Non-hormonal treatment of vulvo-vaginal atrophy-related symptoms in post-menopausal women

References

• Al-Baghdadi O, Ewies AA. 2009. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 12:91–105.
   PubMed Web of Science ®Google Scholar
• Antoine C, Ameye L, Paesmans M, Rozenberg S. 2014. Treatment of climacteric symptoms in breast cancer patients: A retrospective study from a medication databank. Maturitas 78:228–232.
   PubMed Web of Science ®Google Scholar
• Brown MB, Jones SA. 2005. Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. Journal of the European Academy of Dermatology and Venereology 19:308–318.
   PubMed Web of Science ®Google Scholar
• Caillouette JC, Sharp CF Jr, Zimmerman GJ, Roy S. 1997. Vaginal pH as a marker for bacterial pathogens and menopausal status. American Journal of Obstetrics and Gynecology 176:1270–1275; discussion 1275–7.
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Julia MD. 2005. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 52:S46–S52.
   PubMed Web of Science ®Google Scholar
• Cayan F, Dilek U, Pata O, Dilek S. 2008. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women. The Journal of Sexual Medicine 5:132–138.
   PubMed Web of Science ®Google Scholar
• Chan RC, Reid G, Irvin RT, Bruce AW, Coterton JW. 1985. Competitive exclusion of uropathogens from human uroepithelial cells by Lactobacillus whole cells and cell wall fragments. Infection and Immunity 47:84–89.
   PubMed Web of Science ®Google Scholar
• Chen J, Geng L, Song X, Li H, Giordan N, Liao Q. 2013. Evaluation of the Efficacy and Safety of Hyaluronic Acid Vaginal Gel to Ease Vaginal Dryness: A Multicenter, Randomized, Controlled, Open-Label, Parallel-Group, Clinical Trial. The Journal of Sexual Medicine 10:1575–1584.
   PubMed Web of Science ®Google Scholar
• Dew JE, Wren BG, Eden JA. 2003. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 6:45–52.
   PubMed Web of Science ®Google Scholar
• Ewertz M, Jensen AB. 2011. Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol 50:187–193.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. 2000. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. Journal of the National Cancer Institute 92:1054–1064.
   PubMed Web of Science ®Google Scholar
• Haspels AA, Luisi M, Kicovic PM. 1981. Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol. Maturitas 3:321–327.
   PubMed Web of Science ®Google Scholar
• Hickey M, Peate M, Saunders CM, Friedlander M. 2009. Breast cancer in young women and its impact on reproductive function. Human Reproduction Update 15:323–339.
   PubMed Web of Science ®Google Scholar
• Kwan KW, Chlebowski RT. 2009. Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer. Clinical Breast Cancer 9: 219–224.
   PubMed Web of Science ®Google Scholar
• Lima SM, Yamada SS, Reis BF, Postigo S, Galvão da Silva MA, Aoki T. 2013. Effective treatment of vaginal atrophy with isoflavone vaginal gel. Maturitas 74:252–258.
   PubMed Web of Science ®Google Scholar
• Meisels A. 1967. The maturation value. Acta Cytologica 11:249–253.
   PubMed Web of Science ®Google Scholar
• Morales L, Neven P, Timmerman D, Christiaens MR, Vergote I, Van Limbergen E, et al. 2004. Acute effects of tamoxifen and third- generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anti-cancer Drugs 15:753–760.
   PubMed Web of Science ®Google Scholar
• Paavonen J. 1983. Physiology and ecology of the vagina. Scandinavian Journal of Infectious Diseases. Supplementum 40:31–35.
   PubMedGoogle Scholar
• Palacios S, Castelo-Branco C, Cancelo MJ, Vázquez F. 2005. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas 50:98–104.
   PubMed Web of Science ®Google Scholar
• Raffi RO, Moghissi KS, Sacco AG. 1977. Proteins of human vaginal fluid. Fertility and Sterility 28:1345–1348.
   PubMed Web of Science ®Google Scholar
• Raz R, Stamm WE. 1993. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infection. The New England Journal of Medicine 329:753–756.
   PubMed Web of Science ®Google Scholar
• Robinson D, Cardozo LD. 2003. The role of estrogens in female lower urinary tract dysfunction. Urology 62:45–51.
   PubMed Web of Science ®Google Scholar
• Semmens JP, Tsai CC, Semmens EC, Loadholt CB. 1985. Effects of estrogen therapy on vaginal physiology during menopause. Obstetrics and Gynecology 66:15–18.
   PubMed Web of Science ®Google Scholar
• Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. 2008. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstetrics and Gynecology 112:1053–1060.
   PubMed Web of Science ®Google Scholar
• Smith P. 1993. Estrogens and the urogenital tract. Studies on steroid hormone receptors and a clinical study on a new estradiol-releasing vaginal ring. Acta Obstetricia Gynecologica Scandinavica Suppl 157:1–26.
   Google Scholar
• Vassilopoulou-Sellin R, Theriault R, Klein MJ. 1997. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 65:89–93.
   PubMed Web of Science ®Google Scholar
• Wilmoth MC, Botchway P. 1999. Psychosexual implications of breast and gynecologic cancer. Cancer Investigation 17:631–636.
   PubMed Web of Science ®Google Scholar